TippingPoint Biosciences is an early-stage therapeutic company with a novel drug discovery platform to identify first-in-class drugs aimed at treating diseases related to dysfunctional DNA packaging (chromatin). TippingPoint Bio is the first to develop a screening platform to enable direct targeting of the defective chromatin in disease cells without affecting healthy cells. The platform can be applied to multiple disease areas like cancer, neurodegenerative diseases and developmental disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/04/24 | undisclosed | Pre-Seed |
Brightedge Pediatric Brain Tumor Foundation Sontag Family Trust Yuvaan Tiwari Foundation | undisclosed |
